Nom du produit:(1S,3S,4R)-Ethyl2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]oct-5-ene-3-carboxylate
IUPAC Name:ethyl (1S,3S,4R)-2-[(1R)-1-phenylethyl]-2-azabicyclo[2.2.2]oct-5-ene-3-carboxylate
- CAS:134984-64-8
- Formule moléculaire:C18H23NO2
- Pureté:97%
- Numéro de catalogue:CM494928
- Poids moléculaire:285.39
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:134984-64-8
- Formule moléculaire:C18H23NO2
- Point de fusion:-
- Code SMILES:O=C([C@H]1N([C@@H](C2=CC=CC=C2)C)[C@]3([H])C=C[C@@]1([H])CC3)OCC
- Densité:
- Numéro de catalogue:CM494928
- Poids moléculaire:285.39
- Point d'ébullition:
- N° Mdl:MFCD27978833
- Stockage:
Column Infos
- DSP-5336
- Sumitomo Pharma announces that DSP-5336 has received FDA Fast Track Designation for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a KMT2A rearrangement, also known as, mixed lineage leukemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). Menin serves as a tumor suppressor in endocrine glands. Novel menin inhibitors are novel targeted agents in clinical studies targeting genetically defined subsets of acute leukemia.
DSP-5336 is an investigational menin-MLL interaction inhibitor. DSP-5336 has been granted Orphan Drug Designation in acute myeloid leukemia, and Fast Track Designation in relapsed or refractory acute myeloid leukemia with MLLr or NPM1m.